An example is NG-monomethyl-l-arginine (L-NMMA), a known NOS inhibitor, which, when combined with taxane, showed enhanced survival in patients with triple-negative breast cancer and locally advanced breast cancer (NCT02834403, [58]). The gene discussed is NOS1; the disease is triple-negative breast carcinoma.